Valuation: Orexo AB

Market Cap 447M 45.32M 39.52M 37.32M 33.89M 63.49M 4.35B 63.75M 172M 2.21B 170M 166M 7.11B P/E 2026 *
-1.22x
P/E 2027 * -1.76x
Enterprise Value 342M 34.68M 30.24M 28.55M 25.93M 48.58M 3.33B 48.78M 132M 1.69B 130M 127M 5.44B EV / Sales 2026 *
18x
EV / Sales 2027 * 16.6x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-3.61%
Current month-18.47%
1 month-11.72%
3 months-39.05%
6 months-43.74%
Current year-57.48%
1 week 12.72
Extreme 12.72
13.86
1 month 12.72
Extreme 12.72
16.6
Current year 12.72
Extreme 12.72
36
1 year 12.72
Extreme 12.72
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-3.61%-55.79%-24.88% 45.32M
-0.19%+2.04%+80.19%+36.80% 362B
-1.22%-1.22%+19.95%-17.53% 64.74B
+2.53%+4.90%+44.52%+182.75% 12.76B
-0.29%+2.94%-4.00%-16.51% 7.53B
-1.89%-2.14%-31.54%-13.67% 4.38B
-2.06%-4.41%-36.00%+2.04% 4.08B
+1.48%+3.64%-29.60%-14.61% 2.96B
-2.14%+0.86%-8.77%+47.68% 2.44B
-0.41%+1.15%-23.58%-31.98% 1.93B
Average -0.45%+0.06%-4.46%+15.01% 46.32B
Weighted average by Cap. -0.29%+1.55%+65.72%+31.02%

Financials

2026 *2027 *
Net sales 19M 1.93M 1.68M 1.59M 1.44M 2.7M 185M 2.71M 7.33M 93.98M 7.24M 7.08M 302M 27M 2.74M 2.39M 2.25M 2.05M 3.83M 263M 3.85M 10.42M 134M 10.28M 10.06M 430M
Net income -375M -38.02M -33.16M -31.31M -28.43M -53.26M -3.65B -53.49M -145M -1.85B -143M -140M -5.97B -
Net Debt -105M -10.65M -9.28M -8.77M -7.96M -14.91M -1.02B -14.98M -40.52M -519M -39.99M -39.1M -1.67B -
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
18/09/26 SEK 12.80 -0.31% 20,269
17/09/26 SEK 12.84 +0.78% 10,200
16/09/26 SEK 12.74 -1.55% 23,102
15/09/26 SEK 12.94 -0.77% 2,757
14/09/26 SEK 13.04 -1.81% 22,485
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!